首頁
Andelyn Biosciences

11月 2025Andelyn Biosciences的市場佔有率分析

Andelyn Biosciences, born from Nationwide Children's Hospital's breakthroughs in gene therapy, excels in development and CDMO with a mission to expedite innovative therapy delivery to patients.

行業: N/A

域名andelynbio.com

成立年份2006

僱員51 - 200

年度營收$5M - $10M

Andelyn Biosciences

Andelyn Biosciences（包含公司地區）

andelynbio.com

查看更多網站流量與參與度資訊

Andelyn Biosciences截至 11月 2025 的總收入為 5M - 10M

Andelyn Biosciences 熱門網域產生的總收入

Andelyn Biosciences 熱門網域 3 年內的總收入

Andelyn Biosciences 熱門網域的總收入

andelynbio.com5M - 10M

透過銷售情報查看更多內容

Andelyn Biosciences的熱門網域總造訪量

了解Andelyn Biosciences市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

andelynbio.com6.1K

透過銷售情報查看更多內容

Andelyn Biosciences的熱門網域平均造訪時長

分析Andelyn Biosciences參與度指標。

過去 3 個月平均造訪時長

子公司細目

andelynbio.com00:00:38

透過銷售情報查看更多內容

Andelyn Biosciences的熱門網域平均頁面瀏覽量

了解Andelyn Biosciences如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

andelynbio.com2.35

透過銷售情報查看更多內容

Andelyn Biosciences按網域劃分的熱門競爭對手

11月 2025的熱門類似網站，依相似度排名

cariboubio.com公司名Caribou Biosciences僱員51 - 200總部美國, 加利福尼亞, Berkeley年度營收$5M - $10M訪問總量12.3K科學與教育 > 生物學

使用的熱門技術Andelyn Biosciences

这些是Andelyn Biosciences顶级域名使用的行业网站技术

付費廣告 (11)

Google Adsense

付款與貨幣 (8)

Cart Functionality

市場行銷 (5)

Google Marketing Platform

轉換與分析 (4)

Google Analytics

更多技術

12

檢視所有

新聞與訊號來自Andelyn Biosciences

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Andelyn Biosciences, Inc partnered with Jaguar Gene Therapy, LLC on Dec 8th '25.COLUMBUS, Ohio, Dec. 8, 2025 /PRNewswire/ - Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Jaguar Gene Therapy to perform late-stage Process Performance Qualification (PPQ) manufacturing of JAG201, an investigational gene therapy targeting SHANK3 haploinsufficiency which is clinically diagnosed as Phelan-McDermid syndrome (PMS), a leading monogenic cause of autism spectrum disorder (ASD).

新聞Solid Biosciences Inc. partners with Andelyn Biosciences, Inc.Solid Biosciences announces licensing agreement with Andelyn Biosciences for the use of proprietary next-generation capsid AAV-SLB101.

新聞Andelyn Biosciences, Inc partnered with Tern Therapeutics, LLC. on Sep 3rd '25.COLUMBUS, Ohio, Sept. 3, 2025 /PRNewswire/ - Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Tern Therapeutics (Tern) to perform late-stage Process Performance Qualification (PPQ) manufacturing of Tern's TTX-381 program.